SyntheticMR proposes election of new board member

The Nomination Committee of SyntheticMR has proposed to the Annual General Meeting 2022 that the Board will comprise five ordinary members without deputies. The proposed election of Ann-Christine Sundell will be in addition to the re-election of the current board members Staffan Persson, Petra Apell, Johan Sedihn, and Jan Bertus Marten Warntjes.

Ann-Christine Sundell, born in 1964, has extensive experience from leading positions and board assignments in medtech and diagnostics, including global market expansion, product development and the establishment of national screening programs. She has had a long and successful career, including in PerkinElmer, where she was responsible for the Genetic Screening division, a rapidly growing business unit in a globally leading position. She is currently a board member of Medix Biochemica, Actim, Biocartis, Revenio and Immunovia AB (publ).

Other proposals from the Nomination Committee will be presented in the notice to attend the 2022 Annual General Meeting.

For more information, please contact the Chairman of the Board, Johan Sedihn, johan.sedihn@btinternet.com, tel: + 44 7920 154333

SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB has developed SyMRI®, delivering multiple, adjustable contrast images and quantitative data from a single 5-minute scan. The SyMRI product is available in different packages. SyMRI NEURO delivers multiple contrast images, tissue segmentations and quantitative data on the brain. SyMRI KNEE and SyMRI SPINE provides multiple contrast images and quantitative data for knee and spine anatomies. SyMRI NEURO is CE-marked and FDA 510(k) cleared and SyMRI KNEE and SyMRI SPINE is CE-marked. SyMRI is a registered trademark in Europe and the USA. SyntheticMR is listed on the Spotlight Stock Market Exchange in Stockholm, Sweden. For more information, visit www.syntheticmr.com.